Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2017 Nov 17:532–557. doi: 10.1016/B978-0-323-44450-7.00011-4

Ferrets

James K Morrisey 1,2, Matthew S Johnston 1,2
Editors: James W Carpenter1,2, Christopher J Marion1,2
PMCID: PMC7152062

graphic file with name u11-01-9780323444507.jpg

Table 11-1.

Antimicrobial and Antifungal Agents Used in Ferrets.

Agent Dosage Comments
Amikacin 8-16 mg/kg SC, IM, IV divided q8-24h53 Potentially ototoxic and nephrotoxic
10-15 mg/kg SC, IM q12h52
Amoxicillin 20 mg/kg PO, SC q12h52
30 mg/kg PO q8h × 21 days16 Helicobacter; can use with metronidazole and bismuth subsalicylate
Amoxicillin/clavulanic acid (Clavamox, Zoetis) 13-25 mg/kg PO q8-12h52
18.75 mg per jill PO q12h15 For treatment of E. coli induced mastitis
Amphotericin B 0.15 mg/kg IV 3×/wk × 2-4 mon25 Treatment of cryptococcosis
0.25-1 mg/kg IV q24h or q48h until total dose of 7-25 mg has been given25
0.4-0.8 mg/kg IV q7d52 Blastomycosis; monitor for azotemia; total dose 7-25 mg
Ampicillin 5-30 mg/kg SC, IM, IV q8-12h51,52
Azithromycin 5 mg/kg PO q24h60
Cefadroxil 15-20 mg/kg PO q12h52
Cefovecin (Convenia, Zoetis) 8 mg/kg SC q2-3d49 Second generation parenteral cephalosporin; long-acting antibiotic
Cephalexin 15-30 mg/kg PO q8-12h53
Cephaloridine 10-25 mg/kg SC, IM q24h × 5-7 days53 Dermatitis
Chloramphenicol 25-50 mg/kg PO, SC, IM, IV q12h53 14-day minimum for proliferative bowel disease
50 mg/kg SC, IM q12h15 For treatment of mastitis
Ciprofloxacin 10-30 mg/kg PO q24h53 Mix 500 mg tablet in 10 mL water (50 mg/mL); flavor for improved acceptance
Clarithromycin 12.5 mg/kg PO q8-12h × 14 days44 Helicobacter; use with ranitidine bismuth citrate
50 mg/kg PO q24h or divided q12h × 14 days51 Helicobacter; use with omeprazole (or ranitidine) and metronidazole
Clindamycin 5.5-10 mg/kg PO q12h53 Anaerobic infections; bone and dental disease
12.5 mg/kg PO q12h53 Toxoplasmosis
Cloxacillin 10 mg/kg PO, IM, IV q6h65
Doxycycline 10 mg/kg PO q12h37 May help with ferret systemic coronavirus infection
Enrofloxacin (Baytril, Bayer) 5 mg/kg PO, IM q12h15 For treatment of mastitis
5-10 mg/kg PO, SC, IM q12h53 IM for short term (generally 1 injection); injectable form can be given PO in palatable liquid; liquid for PO can also be compounded
10-20 mg/kg PO, SC, IM q12-24h52
Erythromycin 10 mg/kg PO q6h52
220 g/ton feed53 Controlling Campylobacter diarrhea in large groups
Fluconazole 50 mg/kg PO q12h53
Gentamicin 2 mg/kg PO q12h × 10-14 days21 Parenteral form can be given PO; proliferative colitis that is nonresponsive to chloramphenicol12,21
2-5 mg/kg SC, IM, IV q12-24h52 If given IV, dilute with saline and administer over 20 min
Griseofulvin 25 mg/kg PO q12-24h53 Refractory dermatomycosis; use with lime-sulfur dips q7d
Itraconazole 1.5 mg/kg PO q24h41 Invasive nasal cryptococcosis
10 mg/kg PO q12h20 Histoplasmosis
10-20 mg/kg PO q24h67 Cryptococcosis
25-33 mg/kg PO q24h25,72
Ketoconazole 10-50 mg/kg PO q12-24h39
Lime sulfur Dip q7d52 Dermatomycosis; see griseofulvin
Lincomycin 11 mg/kg PO q8h53
Metronidazole 15-20 mg/kg PO q12h52 Anaerobic infections; can use with amoxicillin and bismuth subsalicylate for Helicobacter
Neomycin 10-20 mg/kg PO q6h52 Potential nephrotoxicity and neuromuscular blockage
Netilmicin (Netromycin, Schering) 6-8 mg/kg SC, IM, IV q24h53 Severe staphylococcal infections
Nitazoxanide (Alinia, Romark Laboratories) 5 mg/kg PO q12h25 Treatment of cryptosporidiosis
Oxytetracycline 20 mg/kg PO q8h52
Penicillin G (sodium or potassium) 20,000 U/kg IM q12h39
40,000 U/kg SC, IM q24h52
Pentamidine isethionate 3-4 mg/kg SC q48h25 Pneumocystis pneumonia
Pyremethamine 0.5 mg/kg PO q12h25 Combine with trimethoprim sulfa (30 mg/kg PO q12h) and folic acid (3-5 mg/kg PO q24h) for treatment of toxoplasmosis
Sulfadimethoxine 25 mg/kg PO, SC, IM q24h53
30-50 mg/kg PO q12-24h52
Sulfamethazine 1-5 mg/mL drinking water52
Sulfasoxazole 50 mg/kg PO q8h53
Sulfathalidine Mix in food at dose of 1 g/day/kg body weight12 Opioid useful for management of Salmonella and to reduce shedding in colonies
Tetracycline 20-25 mg/kg PO q8-12h52
Trimethoprim/sulfa 5 mg/kg PO q24h15 Pyelonephritis
15 mg/kg IV q12h8
15-30 mg/kg PO, SC q12h52 Dosage amount of combined drugs
Tylosin (Tylan, Elanco) 5-10 mg/kg PO, SC, IM, IV q12h51,52

Table 11-2.

Antiparasitic Agents Used in Ferrets.

Agent Dosage Comments
Amitraz (Mitaban, Upjohn) 0.0125% topical solution q7d × 3 treatments, then 0.0375% q7d × 3 treatments52 Demodecosis secondary to other illness
0.03% topical solution to affected area q7d × 3-6 treatments53 Demodecosis; use full concentration
Amprolium 19 mg/kg PO q24h52 Coccidiosis
100 mg/kg PO in food or water for 7 days25 Isospora
Carbaryl powder (5%) Topical q7d × 3-6 treatments52 Ectoparasites
Decoquinate 0.5 mg/kg PO for at least 2 wk60 Coccidiosis; larger groups of ferrets
Fenbendazole 20 mg/kg PO q24h × 5 days52
50 mg/kg PO q24h × 30 days52 Mesocestoides infection
Fipronil (Frontline, Merial) 1 pump of spray or ⅕-½ of cat pipette topical q60d52 Flea adulticide
0.2-0.4 mL topically q30d52
Imidacloprid (Advantage, Bayer) 10 mg/kg topically36 Flea treatment; PD
0.1-0.4 mL topically q30d39,52 Flea adulticide; use small cat/kitten vial
Imidacloprid/moxidectin (Advantage Multi, Bayer) 1.9-3.3 μg/kg topically q30d60 Heartworm prevention
Ivermectin 0.02 mg/kg PO, SC q30d69 Heartworm prevention
0.05 mg/kg PO q30d until negative testing69 Recommended treatment for heartworms; give prednisolone (1 mg/kg/day) concurrently
0.05-0.3 mg/kg PO q24h for 1 mo after negative skin scraping6 Demodecosis
0.2-0.5 mg/kg SC q14d × 3 treatments52 Sarcoptic mange
0.4 mg/kg PO, SC, repeat in 14-28 days52 Ear mites, ticks
0.5-1 mg/kg in ears, repeat in 14 days52 Ear mites; half dose in each ear; treat cats and dogs in house concurrently
Lime sulfur Dip 1:40 dilution q7d × 6 wk21 Demodectic mange
Lufenuron (Program, Novartis) 10 mg/kg SC25 Flea larvicide
30 mg/kg PO in food25
30-45 mg/kg PO q30d52
Mebendazole 50 mg/kg PO q12h × 2 days25 Nematodes
Melarsomine dihydrochloride (Immiticide, Merial) 2.5 mg/kg IM once, repeat in 30 days with 2 treatments 24 hr apart52 Heartworm adulticide; less commonly used; use prednisone (1 mg/kg q24h × 4 mo) following treatment
Metronidazole 15-20 mg/kg PO q12h × 14 days52 Gastrointestinal protozoa
Milbemycin oxime (Interceptor, Novartis) 1.15-2.33 mg/kg PO q30d52 Heartworm preventive
Moxidectin 0.17 mg SC once60 Heartworm adulticide
Paromomycin 165 mg/kg PO q12h × 5 days60 Cryptosporidiosis; possible treatment; use with caution, severe renal disease possible
Piperazine citrate 50-100 mg/kg PO q14d53 Intestinal nematodes
Praziquantel (Droncit, Bayer) 5-10 mg/kg PO, SC, repeat in 1053-14d52 Cestodes
25 mg/kg PO × 3 days60 Trematodes
Pyrantel pamoate 4.4 mg/kg PO, repeat in 14 days52
Pyrethrins Topical q7d prn52 Fleas; use products safe for puppies and kittens
Pyrimethamine 0.5 mg/kg PO q12h25 Toxoplasmosis; antiprotozoal
Selamectin (Revolution, Zoetis) 6-18 mg/kg topically51, 52, 53,60 Ectoparasites (fleas, lice, most mites except Demodex)
15 mg topically q30d14 Ear mites, fleas; PD
45 mg/ferret topically50 Ear mites; although this dose has been reported in a PD study, it appears that lower (safer?) doses (see previous) are also quite effective
Sulfadimethoxine 20-50 mg/kg PO q24h7 Coccidia
50 mg/kg PO, then 25 mg/kg q24h × 9 days52
0.5 mL/kg of a 12.5% solution mixed into drinking water56 For treatment of enteric coccidiosis in a large group of ferrets
Thiabendazole/dex-amethasone/neomycin (Tresaderm, Merial) 2 drops in each ear q24h × 7 days, off 7 days, on 7 days55 Ear mites

Table 11-3.

Chemical Restraint/Anesthetic Agents Used in Ferrets.

Agent Dosage Comments
Acepromazine See ketamine for combination
0.1-0.25 mg/kg SC, IM52 Preanesthetic; light sedation
0.1-0.5 mg/kg SC, IM33 Rapid onset of sedation if given IM; doses above 0.2 mg/kg are associated with prolonged recovery times and hypothermia
0.2-0.5 mg/kg SC, IM52 Tranquilization
Alfaxalone (Alfaxan, Jurox) 5 mg/kg IV18 Anesthetic induction; PD
5-15 mg/kg IM28 Sedative
Atipamezole (Antisedan, Zoetis) 0.4 mg/kg IM53
1 mg/kg SC, IV, IP52
Dexmedetomidine and medetomidine reversal; give same volume SC, IV, IP as medetomidine or dexmedetomidine (5 × medetomidine or 10 × dexmedetomidine dose in mg)
Atropine 0.04-0.05 mg/kg SC, IM, IV52 Preanesthetic; bradycardia; hypersalivation
Bupivacaine 1 mg/kg epidurally52 Epidural anesthesia; analgesia
1-1.5 mg/kg SC infiltrate27 Local anesthesia; lasts several hours
Butorphanol Loading dose 0.05-0.2 mg/kg; maintenance 0.1-0.4 mg/kg/hr21 Constant-rate infusion (CRI) for perioperative analgesia; see ketamine, midazolam, and tiletamine/zolazepam for combinations
Dexmedetomidine (Dexdomitor, Zoetis) 0.04-0.1 mg/kg IM49 α2 agonist similar to medetomidine; not commonly used because of bradycardia and other side effects
Diazepam See ketamine for combinations; drug is slowly and incompletely absorbed following IM administration
0.5 mg/kg PO, IM, IV q6-8 h59 Smooth muscle relaxation in urethral obstruction cases
0.5-1.5 mg/kg/h constant-rate infusion3 Seizure control
1 mg/animal IV52 Seizure control; 1-2 boluses
2 mg/kg SC, IM25 Tranquilization; seizure control
Enflurane 2% maintenance52 Anesthesia
Etomidate 1 mg/kg IV27 Induction and intubation of critically ill animal
Fentanyl citrate/fluanisone (Hypnorm, Janssen) 0.3 mg/kg IM52 Anesthesia; not available in the United States
Fentanyl/droperidol (Innovar-Vet, Schering Plough) 0.15 mL/kg IM52 Minor surgical procedures; deep sedation
Glycopyrrolate 0.01 mg/kg IM52 Preanesthetic; bradycardia; hypersalivation
Isoflurane To effect32 Inhalant anesthesia
Ketamine Ketamine combinations follow
10-20 mg/kg IM52 Tranquilization; induction
30-60 mg/kg IM52 Anesthesia; when used alone, high doses cause poor muscle relaxation, rough recoveries, and convulsions; not recommended as a sole agent
Ketamine (K)/acepromazine (A) (K) 20-35 mg/kg + (A) 0.2-0.35 mg/kg SC, IM52 Anesthesia
Ketamine (K)/diazepam (D) (K) 10-20 mg/kg + (D) 1-2 mg/kg IM52 Anesthesia; poor analgesia61
0.1 mL/kg IV52 Induction; will allow intubation with premedication; use equal volumes of (K) at 100 mg/mL and (D) at 5 mg/mL
Ketamine (K)/dexmedetomidine (D) (K) 5 mg/kg IM + (D) 0.03 mg/kg IM52 Medetomidine no longer commercially available; dexmedetomidine at half the dose of medetomidine may be effective
Ketamine (K)/medetomidine (M) or dexmedetomidine (D)/butorphanol (B) (K) 5 mg/kg + (M) 0.08 mg/kg or (D) 0.04 mg/kg + (B) 0.2 mg/kg IM32 Medetomidine no longer commercially available; induction or total injectable anesthesia; allows for intubation; 60-80 min of surgical plane of anesthesia
Ketamine (K)/midazolam (M) (K) 5-10 mg/kg + (M) 0.25-0.5 mg/kg IV51
0.1 mL/kg IV52 Induction; use equal volumes of (K) at 100 mg/mL and (M) at 5 mg/mL
Ketamine (K)/xylazine (X) (K) 10-25 mg/kg + (X) 1-2 mg/kg IM52 Anesthesia; avoid in sick animals;39 may result in cardiac arrhythmias61
Lidocaine 1-2 mg/kg total SC27 Local anesthesia; use 1%-2% solution; lasts 15-30 min
0.5-1.0 mg/kg IV q12h52
Midazolam (Versed, Roche) See ketamine for combination; can be reversed with flumazenil at same volume
0.25-0.3 mg/kg SC, IM25 Mild sedation; premedication
0.25-0.5 mg/kg SC, IM, IV53
Midazolam (M)/butorphanol (B) (M) 0.2 mg/kg + (B) 0.2 mg/kg IM10,58 Good sedation; premedication for minor procedures (i.e., ultrasonography, endoscopy, etc.); if needed, can follow with gas anesthesia or IV propofol; can reverse midazolam with flumazenil
Naloxone (Narcan, Dupont) 0.01-0.03 mg/kg IM, IV52
0.04 mg/kg SC, IM, IV52
Reversal of opioids; up to 1 mg/kg may be used
Propofol 1-3 mg/kg IV32 Induction when premedicants are used; bradypnea or apnea and hypoxia common; intubation and oxygen insufflation is recommended
2-10 mg/kg IV25 Induction
Sevoflurane To effect51 Inhalant anesthesia
Tiletamine/zolazepam (Telazol, Fort Dodge) Tiletamine/zolazepam combinations follow
12-22 mg/kg IM52 Minor surgical procedures at 22 mg/kg; recovery may be prolonged at higher doses; poor muscle relaxation; rarely indicated
Tiletamine/zolazepam (T)/xylazine (X) 3 mg/kg (T) + 3 mg/kg (X) IM34 Small injection volume; rapid and smooth induction; allows for endotracheal intubation
Tiletamine/zolazepam (T)/xylazine (X)/butorphanol (B) 1.5 mg/kg (T) + 1.5 mg/kg (X) + 0.2 mg/kg (B)34 Small injection volume; rapid and smooth induction; allows for endotracheal intubation; analgesia; profound cardiorespiratory depression necessitates oxygen insufflation
Tiletamine/zolazepam (T)/dexmedetomidine (D)/butorphanol (B) 0.03 mL/kg IM of prepared solution (see comment)32 Telazol powder is reconstituted with 2.5 mL of dexmedetomidine and 2.5 mL of butorphanol (10 mg/mL) to form final volume of 5 mL
Xylazine See ketamine and tiletamine/zolazepam for combinations
0.1-0.5 mg/kg SC, IM53 Tranquilization; may cause hypotension, bradycardia, and arrhythmias; use with care in sick animals
2 mg/kg IM33 Rapid immobilization within 3-5 minutes; associated with arrhythmias, hypotension, bradycardia
Yohimbine (Yobine, Lloyd) 0.2-0.5 mg/kg IV52 Xylazine reversal
0.5-1 mg/kg IM52,53

Table 11-4.

Analgesic Agents Used in Ferrets.

Agent Dosage Comments
Acetylsalicylic acid (aspirin) 0.5-22 mg/kg PO q8-24h52 Analgesia; antiinflammatory; antipyretic; cannot be compounded as molecule is unstable in aqueous solution
Amantadine 3-5 mg/kg PO49 May potentiate other analgesics via NMDA antagonist action
Bupivicaine 1-2 mg/kg SC32
Buprenorphine 12 μg/kg epidurally21 Epidural analgesia/anesthesia
0.04 mg/kg IM q4-6h29 PK
0.01-0.05 mg/kg oral transmucosal, SC, IM, IV q6-12h32,52 Analgesia
Butorphanol See ketamine, midazolam, and tiletamine/zolazepam (see Table 11-3) for anesthetic combinations
0.05-0.5 mg/kg SC, IM q8-12h32,52 Analgesia; lower end of dose may be too low for clinical effect; higher end of dose range may cause profound sedation
0.3 mg/kg SC q2-4h29 PK
Carprofen (Rimadyl, Zoetis) 1-5 mg/kg PO q12-24h21,52 Nonsteroidal antiinflammatory; use caution in animals with gastritis or enteritis
4 mg/kg SC32
Fentanyl citrate 1.25-5 μg/kg/h IV via constant-rate infusion21,49 Postoperative analgesia
10-30 μg/kg/h IV via constant-rate infusion21,49 Perioperative analgesia; administer after loading dose of 5-10 μg/kg IV
Flunixin meglumine (Banamine, Schering) 0.3-2 mg/kg IV, PO, SC
q12-24h52,53
Nonsteroidal antiinflammatory; use caution in animals with gastritis or enteritis; use caution in using drug more than 5 days continuously; mix injectable form with palatable syrup for PO
2.5 mg IM q12h14
Gabapentin 3-5 mg/kg PO q8-24h52 Neurotropic pain; may cause sedation at higher doses
Hydromorphone 0.1 mg/kg SC q1-2h29 Opioid; PK
0.1-0.2 mg/kg SC, IM, IV39
Ibuprofen 1 mg/kg PO q12-24h51 Nonsteroidal antiinflammatory
Ketamine 0.1-0.4 mg/kg/h IV via constant-rate infusion21 Postoperative analgesia
0.3-1.2 mg/kg/h IV via constant-rate infusion21 Perioperative analgesia; administer after 2-5 mg/kg IV loading dose
Ketoprofen (Ketofen, Fort Dodge) 1-3 mg/kg PO, SC, IM q24h53 Nonsteroidal antiinflammatory; use caution with gastritis or enteritis or if using > 5 days
Meloxicam 0.1-0.3 mg/kg PO, SC, IM q24h24,25,27 Nonsteroidal antiinflammatory; monitor liver and kidney values
Meperidine (Demerol, Winthrop-Breon) 5-10 mg/kg SC, IM, IV q2-4h25 Analgesia
Morphine 0.1 mg/kg epidurally21 Analgesia
0.2-5 mg/kg SC, IM q2-6h52 SC administration of 1 mg/kg associated with emesis, excitability, and ptyalism39
Nalbuphine (Nubain, Endo Labs) 0.5-1.5 mg/kg IM, IV q2-3h25 Analgesia
Oxymorphone 0.05-0.2 mg/kg SC, IM, IV
q8-12 h27,52
Analgesia
Pentazocine (Talwin, Sanofi Winthrop) 5-10 mg/kg IM q4h52 Analgesia
Tramadol 5-10 mg/kg PO q12-2425 Analgesia; synergistic with NSAIDs

Table 11-5.

Cardiopulmonary Agents Used in Ferrets.

Agent Dosage Comments
Aminophylline 4-6.6 mg/kg PO, IM, IV q12h52 Bronchodilator
Amlodipine (Norvasc, Pfizer) 0.2-0.4 mg/kg PO q12h28 Vasodilator
Atenolol (Tenormin, ICI) 3.125-6.25 mg/kg PO q24h35,52
6.25 mg/animal PO q24h52
β-adrenergic blocker for hypertrophic cardiomyopathy
Atropine 0.02-0.04 mg/kg SC, IM52 Bradycardia
0.1 mg/kg intratracheal52
Benazepril 0.25-0.5 mg/kg PO q24h35,68 Vasodilator; less nephrotoxic than enalapril
Captopril (Capoten, Squibb) of 12.5 mg tablet/animal PO q48h52 Vasodilator; starting dose, gradually increase to q12-24h; can cause lethargy
Digoxin (Cardoxin, Evsco) 0.005-0.01 mg/kg PO q12-24h52 Positive inotrope for dilated cardiomyopathy; monitor serum levels
Diltiazem (Cardizem, Marion Merrill Dow) 1.5-7.5 mg/kg PO q12h35,52 Calcium channel blocker for hypertrophic cardiomyopathy
Dobutamine 0.01 mL/animal IV prn28 Hypotension
Doxapram 1-2 mg/kg IV52 Respiratory stimulant
5-11 mg/kg IV52
Enalapril (Enacard, Merck) 0.25-0.5 mg/kg PO q24-48h35,52 Vasodilator for dilated cardiomyopathy; do not use with concurrent renal disease
Epinephrine 0.02 mg/kg SC, IM, IV, intratracheal43 Cardiac arrest; anaphylactic reactions (including vaccine reactions)
0.2 mg/kg IV, intracardiac, IO25
0.2-0.4 mg/kg diluted in 0.9% NaCl25 intratracheal Administer during cardiopulmonary arrest
Furosemide 1-4 mg/kg PO, SC, IM, IV q8-12h52 Diuretic; use high dose in fulminant heart failure
2-3 mg/kg IM, IV q8-12h followed by 1-2 mg/kg PO q12h for long-term management69 Emergency management of fulminant heart failure
Hyperimmune serum 1 mL/animal IV once57 Use serum from a healthy, appropriately vaccinated ferret for treatment of canine distemper virus infection
Isoproterenol 20-25 μg/animal SC, IM q4-6h69
40-50 μg/animal PO q4-6h69
Positive chronotrope to increase ventricular rate in third-degree AV block
Metaproterenol 0.25-1 mg/kg PO q12h69 Positive chronotrope to increase ventricular rate in third-degree AV block
Nitroglycerin (2%) ointment (Nitrol, Savage) 116- inch/animal q12-24h52 Vasodilator for cardiomyopathy; apply to shaved inner thigh or pinna
Pimobendan 0.25-1.25 mg/kg PO q12h25
0.5 mg/kg PO q12h69
0.625-1.25 mg/kg q12h39
Phosphodiesterase inhibitor; increases cardiac contractility with dilated cardiomyopathy or mitral valve disease
Propranolol (Inderal, Wyeth-Ayerst) 0.2-1 mg/kg PO q8-12h52
2 mg/kg PO, SC q12h52
β-blocker for hypertrophic cardiomyopathy; may cause lethargy, loss of appetite
Pseudophedrine 5 mg/kg PO q8h69 Positive chronotrope to increase ventricular rate in third-degree AV block
Terbutaline 2.5-5 mg/kg PO q12-24h27 Bronchodilator
Theophylline 4.25 mg/kg PO q8-12h12 Bronchodilator; use elixir

Table 11-6.

Adrenal Gland Disease Agents Used in Ferrets.

Agent Dosage Comments
Anastrazole (Arimidex, Astrazeneca Pharmaceuticals) 0.1 mg/kg PO q24h52 Estrogen inhibitor; precursor hormones blocked by inhibition of aromatase enzyme; use until signs resolve, then 7 days on, 7 days off, etc.; pregnant owners should avoid handling agent
Bicalutamide (Casodex, Astrazeneca Pharmaceuticals) 5 mg/kg PO q24h52 Testosterone inhibitor; competitively inhibits androgen by binding to receptors in target tissues; use until clinical signs resolve, then 7 days on, 7 days off, etc.; pregnant owners should avoid handling agent
Deoxycorticosterone pivalate (DOCP) 2 mg/kg IM q21d52 Treatment of adrenal insufficiency following bilateral adrenalectomy
Deslorelin (Suprelorin, Virbac Animal Health) Long-acting GnRH analog that may suppress LH and FSH; used to control signs of adrenal disease; given as a subcutaneous implant approximately once yearly; now available in the United States
2.7 mg implant SC38 Alternative to spay/neuter; the 2.7 mg implant is not available in the United States
3 mg or 4.7 mg SC38,71 The 3 mg implant is not available in the United States
4.7 mg implant SC25 Treatment of adrenal disease; lasts 10-18 months
9.4 mg implant SC25 Treatment of adrenal disease; lasts 16-48 months; not available in the United States
Finasteride (Proscar, Merck) 5 mg/kg PO q24h52 Inhibits conversion of testosterone to active form of dihydrotestosterone; also used in treatment of prostatic enlargement
Flutamide (Eulexin, Schering) 5-10 mg/kg PO q12-24h11,52,63 Androgen inhibitor; reduces enlarged periurethral prostate tissue; lifetime treatment; associated with mammary tumors
Leuprolide acetate (Lupron, AbbVie) Long-acting GnRH analog that may cause an initial stimulation, then suppression of LH and FSH; palliative treatment of adrenal disease (will not resolve tumor); administer q28d until clinical signs regress, then treatment interval can be up to 6-8 wk; lifetime treatment; higher dosage may shrink prostate within 12-48 hr which may improve urine flow in cases of urethral obstruction; must be prepared in aliquots and frozen (although the effects of freezing on drug efficacy are questionable) until used; very expensive
1 mg IM q60-75d11
3 month depot
Adrenal disease
Lupron, Depot 30 day (TAP) 100-150 μg/kg IM q4-8wk1,70
250 μg/kg IM q4-8wk26
Lupron, Depot 4 month (TAP) 250 μg/kg IM59
2 mg/kg SC, IM q16wk52
Melatonin 0.5-1 mg/animal PO q24h61 prn Symptomatic treatment of hyperadrenocorticism; may not affect tumor growth
5.4 mg implant SC52 Should last 6-12 mo
Mitotane (o,p′-DDD) (Lysodren, Bristol-Myers) Hyperadrenocorticism; variable results and not a reliable alternative to adrenalectomy or other drugs mentioned above; results have been largely unsatisfactory and, therefore, use is not recommended
Trilostane (Vetoryl, Dechra) 2 mg/kg PO q12h52 May be useful for treating pituitary-dependent hyperadrenocorticism or adrenal dependent hyperadrenocorticism; reduces synthesis of adrenal androgens

Table 11-7.

Miscellaneous Agents Used in Ferrets.a

Agent Dosage Comments
Activated charcoal 1-3 g/kg PO52 Orally administered adsorbent for gastrointestinal tract toxins/drug overdoses
Amantadine (Symmetrel, Endo Labs) 6 mg/kg as aerosol q12h5,25,52 Influenza; experimental antiviral
Apomorphine 0.7 mg/kg SC52 Emetic
5 mg/kg SC52 Emetic; may cause excitation
Atropine 5-10 mg/kg SC, IM52 Organophosphate toxicity
Azathioprine (Imuran, GlaxoSmithKline) 0.9 mg/kg PO q24-72h9 Immunosuppressive agent; may use in chronic hepatitis
Barium (30%) 8-13 mL/kg PO52 Gastrointestinal contrast study
Barium (60%) 17 mL/kg PO66 Followed 30 minutes later by 42 mL/kg of air for a double contrast gastrointestinal study
Bismuth subcitrate, colloidal 6 mg/kg PO q12h52 In combination with enrofloxacin at 4.25 mg/kg q12h for Helicobacter
Bismuth subsalicylate (Pepto-Bismol, Procter & Gamble) 0.25-1 mL/kg PO q4-8h52 Gastrointestinal ulcers; may help prevent Helicobacter colonization
17.5 mg/kg PO q8-12h52
Bleomycin (Blenoxane, BristolMyersSquibb) 10 U/m2 SC52 Treatment of squamous cell carcinoma
Budesonide (Entocort, Astrazenca) Up to 1 mg/ferret PO q24h49 Novel steroid may have use as single agent treatment for inflammatory bowel disease
Cabergoline 5 μg/kg PO q24h × 5 days27 Pseudopregnancy
Calcium EDTA 20-30 mg/kg SC q12h62 Treatment of heavy metal toxicosis
Chitosan 0.5 mg/kg on food q12h49 Intestinal phosphorus and uremic toxin absorbent; cellulose-like biopolymer from exoskeletons of marine invertebrates
Chlorambucil (Leukeran, Glaxo) 1 mg/kg PO4
20 mg/m2 PO52
Antineoplastic; in chemotherapy protocols for lymphomaa
Chlorpheniramine (Chlor-Trimeton, Squibb) 1-2 mg/kg PO q8-12h52 Antihistamine; control sneezing and coughing when they interfere with eating or sleeping
Cimetidine (Tagamet, SmithKline) 5-10 mg/kg PO, SC, IM q8h52
10 mg/kg PO, IV q8h25
H2 blocker; inhibits acid secretion; gastrointestinal ulcers; unpalatable; give IV (slow)
Ciproheptadine (Periactin, Merck) 0.5 mg/kg PO q12h49 Appetite stimulation
Cisapride (Propulsid, Janssen) 0.5 mg/kg PO q8-12h52 Antiemetic; motility enhancer; not currently available in the United States; must be compounded
Cobalamin 25 μg/kg SC q7d × 6 wk, then q14d × 6 wk, then q30d24 Chronic diarrhea; with cobalamin malabsorption
Cyclophosphamide 10 mg/kg PO, SC52 Antineoplastic; use at higher dose for salvage treatment of lymphomaa
200 mg/m2 PO, SC4
250 mg/m2 PO q4-5wk47 Part of a noninvasive protocol for treatment of lymphomaa
Cyclosporine 4-6 mg/kg PO q12h42 Pure red cell aplasia
Cytarabine (Cytosar-U, Zoetis) 300 mg/m2 q8wk47 Part of a noninvasive protocol for treatment of lymphomaa
Dexamethasone 0.5 mg/kg SC, IM, IV52
1 mg/kg IM52 Post-adrenalectomy; follow with prednisone
Dexamethasone sodium phosphate 1-2 mg/kg IV3 Cerebral edema therapy
2 mg/kg IM, IV19 Anaphylactic reaction to vaccine
4-8 mg/kg IM, IV52 Shock therapy
Dextrose 50% 0.25-2 mL IV40 Bolus for hypoglycemia; give to effect
1.25%-5% IV40 Infusion for hypoglycemic or inappetant animal
Diazoxide (Proglycem, Medical Market Specialties) 5-30 mg/kg PO q12h45,52
10 mg/kg PO q24h or divided q8-12h52
Insulinoma; insulin-blocker; can cause hypertension, lethargy, depression, nausea
Diphenhydramine 0.5-2 mg/kg PO, IM, IV
q8-12h43,52
Antihistamine; controls sneezing and coughing when they interfere with eating or sleeping; give at high dose IM prevaccination when previous reaction occurred or for treatment of vaccine reaction
Doxapram 1-2 mg/kg IV52 Respiratory stimulant
2-5 mg/kg IV53
Doxorubicin 1 mg/kg IV q21d × 4 treatments4 Antineoplastic agent; lymphoma;a salvage treatment
Epinephrine 0.02 mg/kg SC, IM, IV, IT52 Severe vaccine reaction; cardiac arrest
Epoetin alfa (Epogen, Amgen) 50-150 U/kg PO, IM q48h52 Stimulates erythropoiesis; after desired PCV is reached, administer q7d for maintenance
Famotidine (Pepcid, Merck) 0.25-0.5 mg/kg PO, SC, IV q24h52 Inhibits acid secretion; gastrointestinal ulcers
2.5 mg PO, SC, IV q24h25
Fludrocortisone (Florinef, SquibbMark) 0.05-0.1 mg/kg PO q24h or divided q12h52 Mineralocorticoid replacement after adrenal gland removal
Flunixin meglumine (Banamine, Schering) 1 mg/kg SC, IM52 Prevention of prostaglandin-mediated hypotension of endotoxemia
2.5 mg/animal SC, IM q12h prn14 Reduce inflammation in mastitis
Flurbiprofen sodium 1-2 drops q12-24h25 Ophthalmic inflammation
Gadolinium-diethylenetriamine pentaacetic acid (GI-DPTA) (Omniscan, GE Healthcare) 0.2 mL/kg3 MRI contrast agent for neurological studies
Glucagon 15 ng/kg/min IV constant-rate infusion8 Emergency management of hypoglycemia secondary to insulinoma
Glutamine __ Amino acid; L form available OTC as a nutritional supplement; improves immune system, digestive health, and enhances muscle production
0.5 g/kg PO divided daily49 Enterocyte supplementation with starvation
Gonadotropin-releasing hormone (GnRH) (Cystorelin, Sanofi) 20 μg/animal IM14 Termination of estrus after day 10 of estrus; repeat in 2 wk prn
Hairball laxative, feline 1-2 mL/animal PO q48h52 Trichobezoar prophylaxis
Heparin 100 U/animal (0.45-1.35 kg) SC q24h × 21 days35 May be used in some heartworm treatments
200 U/kg SC, IM q12h × 5 days52 Decreases thromboembolism; start day prior to some heartworm adulticide treatments
Human chorionic gonadotropin (hCG) (Pregnyl, Organon) Use 10 or more days after onset of estrus to induce ovulation and prevent hyperestrogenemia; repeat in 1-2 wk prn
50-100 U/animal IM14
200-1000 U/animal IM52
Hydrocortisone sodium succinate 25-40 mg/kg IV52 Shock
Hydrogen peroxide (3%) 2.2 mL/kg PO52 Emetic
Hydroxyzine (Atarax, Roerig) 2 mg/kg PO q8h52 Antihistamine; pruritus; may cause drowsiness
Insulin, glargine 0.5 U SC q12h23
Insulin, NPH 0.1 U/animal SC q12h52
0.5-1 U/kg (or to effect) SC49 Diabetes mellitus; diabetic ketoacidosis; monitor blood glucose
Insulin, ultralente 0.1 U/animal SC q24h52 Diabetes mellitus; monitor blood glucose
Interferon-α 107 units IV or intranasal q24h for several days31 Adjunctive therapy for influenza
Iohexol 0.25-0.5 mL injected epidurally at the L5-L6 intervertebral disc space/kg3 Myelography
10 mL/kg PO52 Gastrointestinal contrast study; can dilute 1:1 with water
2.3 mL/kg IV66 Excretory urography
Ipecac (7%) 2.2-6.6 mL/animal PO52 Emetic
Iron dextran 10 mg/animal IM once49 Iron deficiency anemia; hemorrhage
Isotretinoin 2 mg/kg PO q24h4 Cutaneous epitheliotropic lymphoma
Kaolin/pectin 1-2 mL/kg PO q2-6h prn52 Gastrointestinal protectant
Lactulose syrup (Cephulac, Merrill Dow) 0.15-0.75 mL/kg PO q12h52
150-175 mg/kg PO q8-12h25
Absorption of blood ammonia in hepatic disease; may cause soft stools at higher dose
L-asparaginase 400 U/kg SC, IM4 Antineoplastic
10,000 U/m2 SC q7d × 3 treatments47 Part of a noninvasive chemotherapy protocol
Levothyroxine 50-100 μg/animal q12h72 Hypothyroidism
Loperamide 0.2 mg/kg PO q12h52 Antidiarrheal
Mannitol 0.5-1 g/kg IV3 Give over 20 min
Methotrexate 0.5 mg/kg IV4 Antineoplastic
0.8 mg/kg IM47 Part of noninvasive protocol for treatment of lymphomaa
Metoclopramide 0.2-1 mg/kg PO, SC, IM q6-8h53 Antiemetic; motility enhancer
Milk thistle (Silybum marianum) 4-15 mg/kg PO q8-12h25 Hepatoprotective
Misoprostol (Cytotech, Searle) 1-5 μg/kg PO q8h52 Gastric ulcers
Nandrolone decanoate 1-5 mg/kg IM q7d52 Anabolic steroid
Nutri-Cal (EVSCO) 1-3 mL/animal PO q6-8h52 Nutritional supplement
Octreotide (Sandostatin, Novartis) 1-2 μg/kg SC q8-12h49 Somatostatin analogue; potential treatment for insulinomas
Omeprazole (Prilosec, Astra Merck) 0.7 mg/kg PO q24h17 Proton-pump inhibitor; decreases gastric secretion of HCl
4 mg/kg PO q24h25 Helicobacter; use with clarithromycin and metronidazole
Ondansetron 1 mg/kg PO q12-24h49 Antiemetic
Oseltamivir phosphate (Tamiflu, Genentech) 5-10 mg/kg PO q12h × 10 days31 Antiviral for influenza treatment
Oxytocin 0.2-3 U/kg SC, IM52 Expels retained fetuses; stimulates lactation
Penicillamine 10 mg/kg PO q24h25 Copper toxicity
Pentoxifylline (Pentoxil, Upsher-Smith) 20 mg/kg PO q12h37 Improves perfusion to hypoperfused tissue by increasing deformability of erythrocytes; supportive treatment for ferret systemic coronavirus
Pet-Tinic (SmithKline) 0.2 mL/kg PO q24h52 Nutritional/iron supplement for anemia
Phenobarbital 1-2 mg/kg PO q8-12h39,52 Seizure control
2-10 mg/kg/h IV constant-rate infusion3 Seizure control if diazepam is not effective
Phenoxybenzamine (Dibenzyline, SmithKline Beecham) 3.75-7.5 mg/animal PO
q24-72h59
α-Adrenergic antagonist; smooth muscle relaxation for urethral obstruction; potential gastrointestinal or cardiovascular side effects
Polyprenol (Vetimmune, Sass & Sass) 3 mg/kg PO 3 ×/wk37 Antioxidant and immunostimulant; supportive treatment for ferret systemic coronavirus
Potassium bromide Seizure control
22-30 mg/kg q24h PO3 Dose if used with phenobarbitol
70-80 mg/kg q24h PO3 Dose if used alone
Prazosin (Minipress, Zoetis) 0.05-0.1 mg/kg PO q8h59 α-Adrenergic antagonist; smooth muscle relaxation for urethral obstruction; potential for gastrointestinal and cardiovascular side effects
Prednisone 0.25 mg/kg PO q12h × 5 days, then 0.1 mg/kg q12h × 10 days52 Postoperative adrenalectomy; after initial dose of dexamethasone
0.25-1 mg/kg PO divided q12h52 Insulinoma; gradually increase to 4 mg/kg/day prn; up to 2 mg/kg/day when given with diazoxide
0.5 mg/kg PO q12h × 7-10 days, then q24h × 7-10 days, then q48h × 7-10 days52 Postoperative adrenalectomy
1 mg/kg PO q24h × 7-14 days52 Use following heartworm adulticide treatment; thromboembolism
1.25-2.5 mg/kg PO q24h52 Eosinophilic gastroenteritis; treat until clinical signs abate; gradually decrease to q48h
1.5 mg/kg PO q24h × 7 days, then taper to 0.8 mg/kg PO q24h46 Management of eosinophilic gastroenteritis
2 mg/kg PO q24h52 Palliative therapy for lymphosarcomaa or chronic inflammatory bowel disease; taper dose as able
Procarbazine 50 mg/m2 PO q24h × 14 days4 Part of a noninvasive protocol for treatment of lymphomaa
Proligestone 50 mg SC59 Induce ovulation when jill has been in estrus for 10 days; not available in the United States
Prostaglandin F2-α (Lutalyse, Upjohn) 0.1-0.5 mg/animal IM prn7 Metritis; expels necrotic debris
0.5 mg/animal IM7 Can induce delivery on day 41 if only one kit; follow with 6 U oxytocin 1-4 hr later
Pyridostigmine (Mestinon, Valeant) 1 mg/kg PO q8h13 Oral cholinesterase inhibitor for potential treatment of myasthenia gravis
1 mg/kg PO q8-12h2 Myasthenia gravis; overdose possible with long-term use
Ranitidine bismuth citrate (Pylorid, Glaxo Wellcome) 24 mg/kg PO q8h44 Helicobacter; use in combination with clarithromycin; not available in the United States
Ranitidine HCl (Zantac, Glaxo Wellcome) 3.5 mg/kg PO q12h25,66 Inhibits acid secretion; gastrointestinal ulcers
S-adenosylmethionine (SAMe) (Vetri-SAMe, Vetriscience Labs) 20-100 mg/kg PO q24h49 Adjunctive treatment for liver disease; hepatoprotectant; improves synthesis of glutathione and other compounds important for liver function
Saw palmetto 0.15 mL/animal PO q12h52 Homeopathic remedy used for dysuria associated with prostatic enlargement
Stanozolol (Winstrol, Upjohn) 0.5 mg/kg PO, SC q12h52 Anemia; anabolic steroid; use with caution in hepatic disease
Sucralfate (Carafate, Hoechst Marion Roussel) 25-125 mg/kg PO q8-12h52 Gastrointestinal ulcers; give before meals; requires acidic pH
Sulfasalazine 62.5-125 mg PO q8-24h49 Management of colitis
Theophylline elixir 4.25 mg/kg PO q8-12h52 Bronchodilator
Thyroid-stimulating hormone (TSH) 1 U IV30 Blood for T4 measurement taken 120 min later
Thyroxine 0.2-0.4 mg/kg q12h52 Hypothyroidism; adjust and taper as needed
Trientine (Syprine, Valeant) 10 mg/kg PO q12h25 Chelating agent used for copper toxicosis
Ursodiol (Actigall, Ciba) 15 mg/kg PO q12h9 Treatment of chronic hepatopathies
Vincristine 0.12-0.2 mg/kg IV4
0.75 mg/m2 IV4 Minimal myelosuppression
Vitamin A (retinol palmitate) 50,000 U IM q24h × 2 treatments62 Reduced mortality secondary to canine distemper virus infection
Vitamin B complex 1-2 mg/kg IM prn52 Dose based on thiamine content
Vitamin C 50-100 mg/kg PO q12h25 Adjunct therapy for lymphoma
Vitamin K 2.5 mg/kg SC, then 1-2.5 mg/kg PO divided q8-12h × 5-7 days49 First generation rodenticide toxicity (e.g., warfarin class)
5 mg/kg SC, then 2.5 mg/kg PO divided q8-12h × 3 wk49 Second generation rodenticide
toxicity (e.g., brodifacoum class)
2.5-5 mg/kg SC, then 2.5 mg/kg PO divided q8-12h × 3-4 wk49 Inandione or unknown anticoagulant toxicity
Yeast, brewer’s -14 tsp PO q12h52 Source of chromium to stabilize glucose and insulin for animals with insulinomas
Zanamivir (Relenza, GlaxoSmithKline) 12.5 mg/kg intranasal only5 Antiviral for influenza treatment; greater effect if used with amantadine
0.3-1 mg/kg via inhalation q12h31
a

See Table 11-13 for chemotherapy protocols for lymphoma.

Table 11-8.

Hematologic and Biochemical Values of Ferrets.22,43,52

Measurements Female Male
Hematologya
PCV (%) 34.6-55 33.6-61
RBC (106/μL) 6.77-9.76 7.1-13.2
Hgb (g/dL) 11.9-17.4 12-18.5
MCV (fL) 44.4-53.7 42.6-52.5
MCH (pg) 16.4-19.4 13.7-19.7
MCHC (g/dL) 33.2-42.2 30.3-34.9
WBC (103/μL) 2.5-18.2 4.4-19.1
    • Neutrophils (%)
12-84 11-82
    • Band cells (%)
0-4.2 0-2.2
    • Lymphocytes (%)
12-95 12-73
    • Monocytes (%)
1-8 0-9
    • Eosinophils (%)
0-9 0-8.5
    • Basophils (%)
0-2.9 0-2.7
    • Platelets (103/μL)
264-910 297-730
    • Reticulocytes (%)
2-14 1-12
Biochemistries
ALP (U/L) 3-62 11-120
ALT (U/L) 54-280 54-289
AST (U/L) 40-120 28-248
Bilirubin, total (mg/dL) 0-1 0-0.1
Bile acids (μmol/L) 0.0-28.9 0.0-28.9
BUN (mg/dL) 10-45 11-42
Calcium (mg/dL) 8-10.2 8.3-11.8
Carbon dioxide (mEq/L) 16.5-27.8 12.2-28
Chloride (mEq/L) 112-124 102-126
Cholesterol (mg/dL) 122-296 64-221
Creatinine (mg/dL) 0.2-1 0.2-1
GGT (U/L) 0-5 0-5
Glucose (mg/dL) 85-207 62.5-198
LDH (U/L) 241-752
Lipase (U/L) 0-200
Phosphorus (mg/dL) 4.2-10.1 4-8.7
Potassium (mEq/L) 4.2-7.7 4.1-7.3
Protein, total (g/dL) 5.1-7.2 5.3-7.4
    • Albumin (g/dL)
3.2-4.1 2.8-4.2
    • Globulin (g/dL)
2.2-3.2 2-4
    • Albumin:globulin
1-1.6 0.8-2.1
Sodium (mEq/L) 142-156 137-162
Triglycerides (mg/dL) 10-32
a

Several of these hematology values were obtained from ferrets under isoflurane anesthesia. This can artificially lower red cell indices and may be responsible for the wide ranges in some values.

Table 11-9.

Protein Electrophoresis Values for Ferrets.48

Parameter Normal Values
Total protein (g/dL) 5.6-7.2
Albumin (g/dL) 3.3-4.1
Alpha1 globulins (g/dL) 0.33-0.56
Alpha2 globulins (g/dL) 0.36-0.60
Beta globulins (g/dL) 0.83-1.2
Gamma globulins (g/dL) 0.3-0.8
A/G 1.3-2.1

Table 11-10.

Biologic and Physiologic Data of Ferrets.43,52,64

Parameter Normal Values
Adult body weight, male 1-2 kg
Adult body weight, female 0.65-0.95 kg
Birth weight 6-12 g
Weight at 7 days 30 g average
Weight at 14 days 60-70 g
Sexual maturity 6-12 mo (usually 1st spring after birth)
Reproductive cycle Induced ovulator
Gestation period 42 ± 2 days
Litter size 1-18 (average 8, primiparous jill 10)
Weaning age 6-8 wk
Eyes open 34 days
Hearing 32 days
Life span 5-9 yr (average in United States)
Food consumption 43 g/kg/day
Water consumption 75-100 mL/day
Gastrointestinal transit time 3-4 hr
Enteral feeding requirements 2000-3000 kcal/kg/day
Dental formula 2(I 3/3 C 1/1 P 3/3 M 1/2) = 34
Deciduous teeth erupt 20-28 days
Permanent teeth erupt 50-74 days
Canines erupt 50 days
Molars erupt (first to fourth) 53-74 days
Heart rate 200-400 beats/min
Mean systolic blood pressure 133-161 mmHg
Respiratory rate 33-36 breaths/min
Rectal temperature 37.8-40°C (100-104°F)
Blood volume 60-80 mL (5%-7% body weight)
Intraocular pressure 22.8 ± 5.5 mmHg
Endotracheal tube size 2-4 mm ID
Prothrombin time (PT) 8-16.5 sec
Partial thromboplastin time (PTT) 16-25 sec

Table 11-11.

Urinalysis Values of Ferrets.52

Parameter Male Female
Volume (mL/24 hr) 26 (8-48) 28 (8-140)
Sodium (mmol/24 hr) 1.9 (0.4-6.7) 1.5 (0.2-5.6)
Potassium (mmol/24 hr) 2.9 (1-9.6) 2.1 (0.9-5.4)
Chloride (mmol/24 hr) 2.4 (0.7-8.5) 1.9 (0.3-7.8)
pH 6.5-7.5a 6.5-7.5a
Protein (mg/dL) 7-33 0-32
Exogenous creatinine clearance (mL/min/kg)b 3.32 ± 2.16
Insulin clearance (mL/min/kg) 3.02 ± 1.78
Specific gravity 1.040-1.052 __
a

Urine pH can vary according to diet; normal urine pH in ferrets on a high-quality, meat-based diet is approximately 6.

b

Endogenous creatinine clearance (mL/min/kg) = 2.5 ± 0.93.

Table 11-12.

Proposed Schedule of Vaccinations and Routine Prophylactic Care for Ferrets.43,52

Age Recommendation
4-6 wk CDVa vaccination if dam is unvaccinated
6-8 wk CDVa,b vaccination if dam was vaccinated; physical examination; fecal examination
10-11 wk CDVa, b, c vaccination; physical examination; fecal examination
12-14 wk CDVa, b, c vaccination; rabies vaccination;d physical examination; fecal examination (optional)
4-8 mo Spay/castrate; fecal examination; remove musk glands (optional); start heartworm and flea prevention (endemic areas)
1 yr CDVa,e booster; rabies booster;d physical examination; dental prophylaxis and fecal examination if indicated; CBC; heartworm and flea prevention
2 yr CDVa,e,f booster; rabies booster;d physical examination; dental prophylaxis and fecal examination if indicated; CBC; heartworm and flea prevention
3 yr and older (every 6 mo) CDVa,e,f booster (annual); rabies boosterd (annual); physical examination; dental prophylaxis and fecal examination if indicated; CBC; serum chemistries, including fasting blood glucose; heartworm and flea prevention
a

CDV, canine distemper vaccine; Purevax (Merial) is the only CDV approved for use in ferrets; if Purevax is unavailable, other vaccines which have been used include Novibac DPv (Merck) and Recombitek (Merial).

b

Purevax is recommended to be administered at 8 wk, then every 3 wk for 3 doses.

c

Vaccinations are generally administered at 2-3 wk intervals until the ferret is 12-14 wk of age.

d

Only a killed virus vaccine (Imrab 3, Rhône Merieux) should be used. Vaccines should be separated by several days to reduce vaccine reactions.

e

In previously unvaccinated adults, an initial series of two vaccinations given 14-28 days apart should be given.

f

Rabies and distemper titers are under evaluation and may alter the revaccination schedule of older animals.

Table 11-13.

Chemotherapy Protocols for Lymphoma in Ferrets.a

Protocol I47,52
Week Day Agent Dosage
1 1 Prednisone 1-2 mg/kg PO q12h and continued throughout therapy
1 Vincristine 0.025 mg/kg IV
3 Cyclophosphamide 10 mg/kg PO, SC
2 8 Vincristine 0.025 mg/kg IV
3 15 Vincristine 0.025 mg/kg IV
4 22 Vincristine 0.025 mg/kg IV
24 Cyclophosphamide 10 mg/kg PO, SC
7 46 Cyclophosphamide 10 mg/kg PO, SC
9 63 Prednisone Gradually decrease dose to 0 over the next 4 wk
Protocol IIb,52
Week Agent Dosage
1 Vincristine 0.025 mg/kg IV
L-asparaginase 400 U/kg IP
Prednisone 1 mg/kg PO q24h and continued throughout therapy
2 Cyclophosphamide 10 mg/kg SC
3 Doxorubicin 1 mg/kg IV
4-6 As weeks 1-3 above, but discontinue L-asparaginase
8 Vincristine 0.025 mg/kg IV
10 Cyclophosphamide 10 mg/kg SC
12 Vincristine 0.025 mg/kg IV
14 Methotrexate 0.5 mg/kg IV
Protocol III47
Week Agent Dosage
1 L-asparaginase 10,000 U/m2 SC
Cytoxin 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC)
Prednisone 2 mg/kg PO daily for 7 days, then q48h throughout therapy
2 L-asparaginase 10,000 U/m2 SC
Perform CBCc
3 L-asparaginase 10,000 U/m2 SC
Cytosar 300 mg/m2 SC × 2 days (dilute 100 mg with 1 mL H20)
4 Perform CBCc
5 Cytoxin 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC)
7 Methotrexate Perform CBCc 0.8 mg/kg IM
8 Perform CBCc
9 Cytoxin 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC)
11 Cytosar 300 mg/m2 SC × 2 days (dilute 100 mg with 1 mL H2O)
Leukeran 1 tablet/animal PO or ½ tablet/animal PO × 2 days
12 Perform CBCc
13 Cytoxin 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC)
15 Procarbazine 50 mg/m2 PO q24h × 14 days
16 Perform CBCc
17 Perform CBCc
18 Cytoxin 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC)
20 Cytosar 300 mg/m2 SC × 2 days (dilute 100 mg with 1 mL H2O)
Leukeran 1 tablet/animal PO or ½ tablet/animal PO × 2 days
23 Cytoxin 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC)
26 Procarbazine 50 mg/m2 PO q24h × 14 days
27 Perform CBCc and chemistry panel If not in remission, continue weeks 20-26 for 3 cycles
Protocol IV4
Week Agent Dosage
3 days L-asparaginase 400 U/kg SC (premedicate with diphenhydramine)
1 Vincristine 0.12 mg/kg IV
Prednisone 1 mg/kg PO q24h continue throughout therapy
Cyclophosphamide 10 mg/kg PO
2 Vincristine 0.12 mg/kg IV
3 Vincristine 0.12 mg/kg IV
4 Vincristine 0.12 mg/kg IV
Cyclophosphamide 10 mg/kg PO
7, 10, 13, etc. Vincristine 0.12 mg/kg IV
Cyclophosphamide 10 mg/kg PO
Continue therapy every 3 wk for 1 yr, then decrease to every 4-6 wk
Rescue treatment Doxorubicin 1-2 mg/kg IV (over 20 min)
a

CBC should be checked weekly during therapy; after therapy is discontinued, continue to monitor CBC and do physical examination at 3-mo intervals.

b

Protocol is continued in sequence biweekly after week 14, making the therapy protocol less intensive.

c

If CBC shows severe myelosuppression, reduce dosage by 25% for all subsequent treatments of the previously used myelosuppressive drug.

Table 11-14.

Conversion of Body Weight (kg) to Body Surface Area (m2).47

Body Weight (kg) Body Surface Area (m2)
0.5 0.063
0.6 0.071
0.7 0.079
0.8 0.086
0.9 0.093
1.0 0.100
1.1 0.107
1.2 0.113
1.3 0.119
1.4 0.125
1.5 0.131
1.6 0.137
1.7 0.142
1.8 0.148
1.9 0.153
2.0 0.159
2.1 0.164
2.2 0.169
2.3 0.174
2.4 0.179
2.5 0.184

References

  • 1.Antinoff N. Neoplasia in ferrets. In: Bonagura J.D., editor. Kirk’s Current Veterinary Therapy XIII: Small Animal Practice. WB Saunders Co; Philadelphia: 2000. pp. 1149–1152. [Google Scholar]
  • 2.Antinoff N. Diagnosis and successful treatment of myasthenia gravis in a ferret. ExoticsCon. 2015;367 [Google Scholar]
  • 3.Antinoff N., Giovanella C.J. Musculoskeletal and neurologic diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 132–140. [Google Scholar]
  • 4.Antinoff N., Hahn K. Ferret oncology. Vet Clin North Am Exot Anim Pract. 2004;7:579–626. doi: 10.1016/j.cvex.2004.05.001. [DOI] [PubMed] [Google Scholar]
  • 5.Barron H.W., Rosenthal K.L. Respiratory diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 78–85. [Google Scholar]
  • 6.Beaufrère H., Neta M., Smith D.A. Demodectic mange associated with lymphoma in a ferret. J Exot Pet Med. 2009;18:57–61. [Google Scholar]
  • 7.Bell J.A. Periparturient and neonatal diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 2nd ed. WB Saunders Co; St. Louis: 2004. pp. 50–57. [Google Scholar]
  • 8.Bennett K.R., Gaunt M.C., Parker D.L. Constant rate infusion of glucagon as an emergency treatment for hypoglycemia in a domestic ferret (Mustela putorius furo) J Am Vet Med Assoc. 2015;246:451–454. doi: 10.2460/javma.246.4.451. [DOI] [PubMed] [Google Scholar]
  • 9.Burgess M., Garner M. Clinical aspects of inflammatory bowel disease in ferrets. Exot DVM. 2002;4(2):29–34. [Google Scholar]
  • 10.Carpenter J.W. 2017. Personal observation. [Google Scholar]
  • 11.Chen S., Michels D., Culpepper E. Nonsurgical management of hyperadrenocorticism in ferrets. Vet Clin Exot Anim. 2014;17:35–49. doi: 10.1016/j.cvex.2013.09.001. [DOI] [PubMed] [Google Scholar]
  • 12.Coburn D.R., Morris J.A. The treatment of Salmonella typhimurium infection in ferrets. Cornell Vet. 1949;39:198. [Google Scholar]
  • 13.Couturier J., Huynh M., Boussarie D. Autoimmune myasthenia gravis in a ferret. J Am Vet Med Assoc. 2009;235:1462–1466. doi: 10.2460/javma.235.12.1462. [DOI] [PubMed] [Google Scholar]
  • 14.Fisher M., Beck W., Hutchinson M.J. Efficacy and safety of selamectin (Stronghold®/RevolutionTM) used off-label in exotic pets. Intern J Appl Res Vet Med. 2007;5:87–96. [Google Scholar]
  • 15.Fox J.G., Bell J.A. Diseases of the genitourinary system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 335–361. [Google Scholar]
  • 16.Fox J.G., Lee A. The role of Helicobacter species in newly recognized gastrointestinal diseases of animals. Lab Anim Sci. 1997;47:222–227. [PubMed] [Google Scholar]
  • 17.Fox J.G., Marini R.P. Helicobacter mustelae infection in ferrets: pathogenesis, epizootiology, diagnosis, and treatment. Semin Avian Exot Pet Med. 2001;10:36–44. [Google Scholar]
  • 18.Giral M., Garcia-Olma D.C., Gomez-Juarez M. Anaesthetic effect in the ferret of alfaxalone alone and in combination with medetomidine or tramadol: a pilot study. Lab Anim. 2014;48:313–320. doi: 10.1177/0023677214539150. [DOI] [PubMed] [Google Scholar]
  • 19.Greenacre C.B. Incidence of adverse events in ferrets vaccinated with distemper or rabies vaccine: 143 cases (1995-2001) J Am Vet Med Assoc. 2003;223:663–665. doi: 10.2460/javma.2003.223.663. [DOI] [PubMed] [Google Scholar]
  • 20.Greenacre C.B., Dowling M., Nobrega-Lee M. Histoplasmosis in a group of domestic ferrets (Mustela putorius furo) ExoticsCon. 2015;363 [Google Scholar]
  • 21.Hawkins M.G. Advances in exotic mammal clinical therapeutics. Vet Clin N Am Exot Anim Pract. 2015;18:323–327. doi: 10.1016/j.cvex.2015.01.008. [DOI] [PubMed] [Google Scholar]
  • 22.Hein J., Spreyer F., Sauter-Louis C. Reference ranges for laboratory parameters in ferrets. Vet Rec. 2012;171:218. doi: 10.1136/vr.100628. [DOI] [PubMed] [Google Scholar]
  • 23.Hess L. Insulin glargine treatment of a ferret with diabetes mellitus. J Am Vet Med Assoc. 2012;241:1490–1494. doi: 10.2460/javma.241.11.1490. [DOI] [PubMed] [Google Scholar]
  • 24.Hoppes S.M. The senior ferret. Vet Clin North Am Exot Anim Pract. 2010;13:107–121. doi: 10.1016/j.cvex.2009.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Jepson L. Ferrets. In: Jepson L., editor. Exotic Animal Medicine: A Quick Reference Guide. 2nd ed. Elsevier; St. Louis: 2016. pp. 1–42. [Google Scholar]
  • 26.Johnson D. Current therapies for ferret adrenal disease. Proc Atlantic Coast Vet Conf. 2006:1–7. [Google Scholar]
  • 27.Johnson-Delaney C. Ferrets: anaesthesia and analgesia. In: Keeble E., Meredith A., editors. BSAVA Manual of Rodents and Ferrets. British Small Animal Veterinary Association; Gloucester, UK: 2009. pp. 245–253. [Google Scholar]
  • 28.Johnson-Delaney C.A. CRC Press; Boca Raton: 2017. Ferret Medicine and Surgery; pp. 457–467. [Google Scholar]
  • 29.Katzenbach JE, Wittenburg LA, Allweiler SI, et al. Pharmacokinetics of single-dose buprenorphine, butorphanol, and hydromorphone in the domestic ferret (Mustela putorius furo). J Exot Pet Med. In press.
  • 30.Keeble E. Endocrine diseases in small mammals. In Pract. 2001;23:570–585. [Google Scholar]
  • 31.Kiupel M., Perpinan D. Viral diseases of ferrets. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 439–517. [Google Scholar]
  • 32.Ko J.C., Marini R.P. Anesthesia. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 259–283. [Google Scholar]
  • 33.Ko J.C., Heaton-Jones T.G., Nicklin C.F. Comparison of sedative and cardiorespiratory effects of diazepam, acepromazine, and xylazine in ferrets. J Am Anim Hosp Assoc. 1998;34:234–241. doi: 10.5326/15473317-34-3-234. [DOI] [PubMed] [Google Scholar]
  • 34.Ko J.C., Nicklin C.F., Montgomery T. Comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-xylazine and tiletamine-zolazepam-xylazine-butorphanol in ferrets. J Am Anim Hosp Assoc. 1998;34:164–174. doi: 10.5326/15473317-34-2-164. [DOI] [PubMed] [Google Scholar]
  • 35.Kraus M.S., Morrisey J.K. Cardiovascular and other diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 62–77. [Google Scholar]
  • 36.Larsen K.S., Siggurdsson H., Mencke N. Efficacy of imidacloprid, imidacloprid/permethrin and phoxim for flea control in the Mustelidae (ferrets, mink) Parasitol Res. 2005;97:S107–S112. doi: 10.1007/s00436-005-1453-0. [DOI] [PubMed] [Google Scholar]
  • 37.Lennox A. GI disease in ferrets. Available at: https://www.cliniciansbrief.com/article/gi-disease-ferrets. Published Sept 2013. Accessed May 25, 2017.
  • 38.Lennox A. Alternative surgical options for elective altering in exotic companion mammals. ExoticsCon. 2015:435–444. [Google Scholar]
  • 39.Lewington J.H. Appendix. In: Lewington J.H., editor. Ferret Husbandry, Medicine and Surgery. Butterworth Heinemann; Oxford: 2000. pp. 273–282. [Google Scholar]
  • 40.Longley L. Ferret anaesthesia. In: Longley L., editor. Anaesthesia of Exotic Pets. Saunders/Elsevier; Philadelphia: 2008. pp. 85–95. [Google Scholar]
  • 41.Malik R., Martin P., McGill J. Successful treatment of invasive nasal cryptococcosis in a ferret. Aust Vet J. 2000;78:158–159. doi: 10.1111/j.1751-0813.2000.tb10582.x. [DOI] [PubMed] [Google Scholar]
  • 42.Malka S., Hawkins M.G., Zabolotzky S.M. Immune-mediated pure red cell aplasia in a domestic ferret. J Am Vet Med Assoc. 2010;237:695–700. doi: 10.2460/javma.237.6.695. [DOI] [PubMed] [Google Scholar]
  • 43.Marini R.P. Physical examination, preventive medicine, and diagnosis in the ferret. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 235–258. [Google Scholar]
  • 44.Marini R.P., Fox J.G., Taylor N.S. Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. Am J Vet Res. 1999;60:1280–1286. [PubMed] [Google Scholar]
  • 45.Marini R.P., Ryden E.B., Rosenblad W.D. Functional islet cell tumor in six ferrets. J Am Vet Med Assoc. 1993;202:430–433. [PubMed] [Google Scholar]
  • 46.Maurer K.J., Fox J.G. Diseases of the gastrointestinal system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 363–375. [Google Scholar]
  • 47.Mayer J., Erdman S.E., Fox J.G. Diseases of the hematopoietic system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 311–334. [Google Scholar]
  • 48.Melillo A. Applications of serum protein electrophoresis in exotic mammals. Vet Clin North Am Exot Anim Pract. 2013;16:211–225. doi: 10.1016/j.cvex.2012.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Meredith A. 9th ed. Gloucester; British Small Animal Veterinary Association: 2015. Small Animal Formulary—Part B: Exotic Pets. [Google Scholar]
  • 50.Miller D.S., Eagle R.P., Zabel S. Efficacy and safety of selamectin in the treatment of Otodectes cynotis infestation in domestic ferrets. Vet Rec. 2006;159:748. doi: 10.1136/vr.159.22.748. [DOI] [PubMed] [Google Scholar]
  • 51.Morrisey J.K. Ferrets: therapeutics. In: Keeble E., Meredith A., editors. BSAVA Manual of Rodents and Ferrets. British Small Animal Veterinary Association; Gloucester, UK: 2009. pp. 237–244. [Google Scholar]
  • 52.Morrisey J.K. Ferrets. In: Carpenter J.W., editor. Exotic Animal Formulary. 4th ed. Elsevier Saunders; St. Louis: 2013. pp. 560–594. [Google Scholar]
  • 53.Morrisey J.K., Carpenter J.W. Formulary. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 566–575. [Google Scholar]
  • 54.Neuwirth L., Isaza R., Bellah J. Adrenal neoplasia in seven ferrets. Vet Radiol Ultrasound. 1993;34:340–346. [Google Scholar]
  • 55.Patterson M.M., Kirchain S.M. Comparison of three treatments for control of ear mites in ferrets. Lab Anim Sci. 1999;49:655–657. [PubMed] [Google Scholar]
  • 56.Patterson M.M., Fox J.C., Eberhard M.L. Parasitic diseases. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 553–572. [Google Scholar]
  • 57.Perpinan D., Ramis A., Tomas A. Outbreak of canine distemper in domestic ferrets (Mustela putorius furo) Vet Rec. 2008;163:246–250. doi: 10.1136/vr.163.8.246. [DOI] [PubMed] [Google Scholar]
  • 58.Pinon C., Huynh M. Flexible gastrointestinal endoscopy in ferrets. ExoticsCon. 2015:459–463. doi: 10.1016/j.cvex.2015.05.002. [DOI] [PubMed] [Google Scholar]
  • 59.Pollock C.G. Disorders of the urinary and reproductive systems. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 46–61. [Google Scholar]
  • 60.Powers L.V. Bacterial and parasitic diseases of ferrets. Vet Clin North Am Exot Anim Pract. 2009;12:531–561. doi: 10.1016/j.cvex.2009.06.001. [DOI] [PubMed] [Google Scholar]
  • 61.Ramer J.C., Benson K.G., Morrisey J.K. Effects of melatonin administration on the clinical course of adrenocortical disease in domestic ferrets. J Am Vet Med Assoc. 2006;229:1743–1748. doi: 10.2460/javma.229.11.1743. [DOI] [PubMed] [Google Scholar]
  • 62.Rodeheffer C., von Messling V., Milot S. Disease manifestations of canine distemper virus infection in ferrets are modulated by vitamin A status. J Nutr. 2007;137:1916–1922. doi: 10.1093/jn/137.8.1916. [DOI] [PubMed] [Google Scholar]
  • 63.Rosenthal K.R., Wyre N.R. Endocrine diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 86–102. [Google Scholar]
  • 64.Sapienza J.S., Porcher D., Collins B.R. Tonometry in clinically normal ferrets (Mustela putorius furo) Prog Vet Comp Ophthalmol. 1991;1:291–294. [Google Scholar]
  • 65.Schwarz L.A., Solano M., Manning A. The normal upper gastrointestinal examination in the ferret. Vet Radiol Ultrasound. 2003;44:165–172. doi: 10.1111/j.1740-8261.2003.tb01265.x. [DOI] [PubMed] [Google Scholar]
  • 66.Silverman S., Tell L.A. Elsevier Saunders; St. Louis: 2005. Radiology of Rodents, Rabbits, and Ferrets: an Atlas of Normal Anatomy and Positioning. [Google Scholar]
  • 67.Vella D. Cryptococcosis. In: Mayer J., Donnelly T.M., editors. Clinical Veterinary Advisor: Birds and Exotic Pets. Elsevier Saunders; St. Louis: 2013. p. 439. [Google Scholar]
  • 68.Wagner R.A. Ferret cardiology. Vet Clin North Am Exot Anim Pract. 2009;12:115–134. doi: 10.1016/j.cvex.2008.09.001. [DOI] [PubMed] [Google Scholar]
  • 69.Wagner R.A. Diseases of the cardiovascular system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 401–419. [Google Scholar]
  • 70.Wagner R.A., Bailey E.M., Schneider J.F. Leuprolide acetate treatment of adrenocortical disease in ferrets. J Am Vet Med Assoc. 2001;218:1272–1274. doi: 10.2460/javma.2001.218.1272. [DOI] [PubMed] [Google Scholar]
  • 71.Wagner R.A., Piche C.A., Jöchle W. Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease. Am J Vet Res. 2005;66:910–914. doi: 10.2460/ajvr.2005.66.910. [DOI] [PubMed] [Google Scholar]
  • 72.Wyre N.R., Michels D., Chen S. Selected emerging diseases in ferrets. Vet Clin North Am Exot Anim Pract. 2013;16:469–493. doi: 10.1016/j.cvex.2013.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Exotic Animal Formulary are provided here courtesy of Elsevier

RESOURCES